Patent: 9,884,094
✉ Email this page to a colleague
Summary for Patent: 9,884,094
Title: | Method of treating diabetes mellitus |
Abstract: | A combination comprising at least a first insulin-like compound and a second insulin-like compound for treating a condition or a disease in a subject in need thereof where administration of insulin would be of benefit to said subject is described. The combination is administered in an amount to achieve a beneficial glycaemic control in said subject as determined by the levels of HbA.sub.1c in said subject after administration of said combination at the largest meal of the day for said subject; wherein said beneficial glycaemic control by said combination is superior to any glycaemic control achieved by an equivalent dose of IGlar in said subject as determined by the levels of HbA.sub.1c in said subject after administration of IGlar for said subject and/or wherein said beneficial glycaemic control by said combination comprises decreasing the levels of HbA.sub.1c in said subject to about 7 or less after administration of said combination at the largest meal of the day; wherein said first insulin-like compound is longer acting than the second insulin-like compound; wherein said combination is administered at the largest meal of the day for said subject; wherein said first insulin-like compound is at least a long acting insulin, preferably an ultra long acting insulin; wherein said first insulin-like compound is a derivative of a naturally occurring insulin or is an insulin analog; and wherein said first insulin-like compound has a side chain attached to the a-amino group of the N-terminal amino acid residue of the B chain or to the .epsilon.-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula (I): --W--X--Y--Z. |
Inventor(s): | Johansen; Thue (Koebenhavn, DK), Mersebach; Henriette (Hellerup, DK), Axelsen; Mads (Virum, DK), Lange; Martin (Bagsvaerd, DK) |
Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
Application Number: | 14/398,018 |
Patent Claims: | see list of patent claims |
Details for Patent 9,884,094
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/20/2000 | ⤷ Try a Trial | 2032-05-01 |
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/25/2007 | ⤷ Try a Trial | 2032-05-01 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 12/16/2015 | ⤷ Try a Trial | 2032-05-01 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 11/15/2019 | ⤷ Try a Trial | 2032-05-01 |
Mylan Pharmaceuticals Inc. | SEMGLEE | insulin glargine | Injection | 210605 | 06/11/2020 | ⤷ Try a Trial | 2032-05-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |